(RETA)

業務介紹

瑞塔製藥公司(Reata Pharmaceuticals, Inc.)是一家處於臨床階段的生物製藥公司,負責識別、開發和商業化適用於患有嚴重或危及生命疾病患者的創新療法。該公司正在開發3期臨床試驗計劃,包括用於治療由阿爾波特綜合症引起的慢性腎病(CKD)患者,以及與結締組織疾病相關的肺動脈高血壓的bardoxolone methyl(bardoxolone);正在2期臨床試驗中的omaveloxolone,用於治療弗里德萊希共濟失調;並正在進行2期研究,針對各種形式的慢性腎病,如IgA腎病、1型和2型糖尿病性慢性腎病、高血壓性慢性腎病、局灶性節段性肾小球硬化等。該公司還在開發RTA 901用於神經系統疾病,以及RTA 1701用於治療各種自身免疫、炎症和纖維化疾病。此外,該公司還提供bardoxolone用於治療常染色體顯性多囊腎。該公司還與協和麒麟株式會社(Kyowa Kirin Co., Ltd.)簽訂了戰略合作協議,共同開發和商業化bardoxolone用於治療腎臟、心血管、糖尿病和其他相關代謝適應症,適用於日本、中國、香港、澳門、南韓、台灣、泰國、新加坡、菲律賓、馬來西亞、印尼、汶萊、越南、老撾和緬甸。該公司還與AbbVie Inc.簽訂了聯合研究、開發和商業化所有二代及更高代Nrf2激活劑(不包括腎臟、心血管和代謝適應症)的協議。該公司原名為Reata Discovery, Inc.,於2005年5月更名為Reata Pharmaceuticals, Inc.。該公司成立於2002年,總部位於德克薩斯州普拉諾。



Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.

公司網址

https://www.reatapharma.com